Small-Molecule Id1/Id3 Inhibitors for Chemoresistant Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pathogenic cellular proliferation, angiogenesis, cancer, and metastatic disease are ineffective against chemoresistant 'resting' stem cells and may lead to acquired resistance, as they target proliferative cells while neglecting these resistant cells.
Innovation Solution
Development of small molecule inhibitors targeting Id proteins, specifically Id1 and Id3, to disrupt stem cell identity and impair tumor initiation, potentially combined with conventional chemotherapies, to address chemoresistant cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapies target proliferative cells, then tumor growth is inhibited, but chemoresistant resting stem cells survive and lead to acquired resistance
Solution Approach 1:
Instead of targeting proliferative cells as conventional therapies do, this patent inverts the approach by specifically targeting resting stem cells that maintain tumor-initiating capacity. The small molecule inhibitors (e.g., AGX-502) are designed to bind to and inhibit Id proteins (Id1 and Id3) that are highly expressed in resting stem cells, thereby eliminating the reservoir of chemoresistant cells that conventional therapies miss.
Solution Approach 2:
The patent employs parameter changes by developing small molecule inhibitors with specific molecular structures (Formula I) that target the Id protein pathway. These compounds exhibit optimized pharmacokinetic and pharmacodynamic properties, including selective binding to Id1 and Id3 proteins, enabling them to specifically disrupt stem cell identity and proliferation without affecting differentiated tumor cells that have already been targeted by conventional therapies.
2Reliability
If small molecule inhibitors target Id proteins to disrupt stem cell identity, then tumor initiation is impaired, but the mechanism of action requires high specificity to avoid off-target effects
Solution Approach 1:
The small molecule inhibitors are designed with specific molecular features that confer high local quality for binding to Id proteins. The compounds contain specific structural elements (such as the core heterocyclic ring system and substituent patterns in Formula I) that match the binding pocket of Id1 and Id3 proteins, enabling selective interaction with these targets while minimizing interactions with other proteins that could cause off-target effects.
Data Source
AI summary
The present technology relates generally to compounds, compositions, and methods useful for treating, preventing, and/or ameliorating pathogenic cellular proliferation, angiogenesis, cancer, metastatic disease, and/or a pathogenic vascular proliferative disease in a subject.